BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32573116)

  • 21. Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study.
    Granstam E; Rosenblad A; Modher Raghib A; Granström T; Eriksson JW; Lindholm Olinder A; Leksell J
    Acta Ophthalmol; 2020 Jun; 98(4):360-367. PubMed ID: 31656056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study.
    Abraham JR; Wykoff CC; Arepalli S; Lunasco L; Yu HJ; Hu M; Reese J; Srivastava SK; Brown DM; Ehlers JP
    Am J Ophthalmol; 2021 Feb; 222():328-339. PubMed ID: 32896498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optical Coherence Tomography Features in Diabetic Macular Edema and the Impact on Anti-VEGF Response.
    Itoh Y; Petkovsek D; Kaiser PK; Singh RP; Ehlers JP
    Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):908-913. PubMed ID: 27759856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
    Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
    JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.
    Reznicek L; Bolz M; Garip A; Kampik A; Kernt M; Mayer WJ
    Curr Eye Res; 2016 Aug; 41(8):1082-1086. PubMed ID: 26580417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
    Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
    Mikhail M; Stewart S; Seow F; Hogg R; Lois N
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
    Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
    Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
    Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
    Hong IH; Choi W; Han JR
    Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of anti-VEGF efficacy in diabetic macular oedema using intraocular cytokines and macular optical coherence tomography.
    Mao J; Zhang S; Zheng Z; Deng X; Liu C; Chen Y; Zhao S; Zhang Y; Shen L
    Acta Ophthalmol; 2022 Jun; 100(4):e891-e898. PubMed ID: 34403203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.
    Mori K; Yoshida S; Kobayashi Y; Ishikawa K; Nakao S; Hisatomi T; Haruta M; Isihibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):735-741. PubMed ID: 31960130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting.
    Brito P; Costa J; Gomes N; Costa S; Correia-Pinto J; Silva R
    Acta Ophthalmol; 2020 Jun; 98(4):e421-e427. PubMed ID: 31742896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
    Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
    Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.